Amphastar Pharmaceuticals, Inc. (AMPH)

Every figure this model derived for AMPH, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 31,718,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 290,123,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 630,951,000 AssetsCurrent 2026-06-30
current liabilities 263,205,000 LiabilitiesCurrent 2026-06-30
equity 768,157,000 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 2026-06-30
interest expense 26,126,000 InterestExpenseNonoperating 2026-06-30
ocf 184,610,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 730,019,000 Revenues 2026-06-30
sbc 28,866,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up AMPH on one particular measure came for.

RatioValue
cash operating margin24.0
current ratio2.4
current ratio reported2.4
deferred revenue growth29.08
dilution pct-7.39
ebit cagr1.77
ebit yoy-37.09
fcf margin20.94
growth cv0.67
interest cover4.37
net debt ebitda2.2
operating margin15.66
owner earnings margin16.99
revenue growth1.02
revenue growth per share9.07
roic8.28
rule of 4016.67
sbc pct revenue3.95

What to be careful about

What this model itself distrusts about AMPH's figures. Written by the derivation as it ran, not added afterwards.